Latest research
Latest corporate research
Latest tax enhanced reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact Us
Twitter icon
Created with Sketch.
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax enhanced research
Product reports for investors and advisors
Latest published research
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Services for private Companies
Tax enhanced research
Product reports for investors and advisors.
Bespoke consulting services
Bespoke services
Services for clients with specific needs
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
24: Making big ideas investible and measuring impact | Dan Somers of Boundary Capital
Stay up-to-date with the latest research
Sign up to our newsletter
COVID-19: -
Our Commitment to Client Service & Investor Communications
Life Sciences research
Redx Pharma
Life Sciences
RXC006: first anti-fibrosis development candidate
By
Dr Martin Hall
30 Nov 2018
Redx Pharma
Life Sciences
Streamlined, focused and good value
By
Dr Gregoire Pave
27 Nov 2018
Stay up-to-date with the latest research
Sign up to our newsletter
Chronix Biomedical
Life Sciences
Monitoring treatment, improving outcomes
By
Dr Dorothea Hill
13 Nov 2018
Redx Pharma
Life Sciences
ROCK2 inhibitors in chronic kidney disease
By
Dr Gregoire Pave
09 Nov 2018
Alliance Pharma Plc
Life Sciences
International brands driving performance
By
Dr Dorothea Hill
07 Nov 2018
ValiRx
Life Sciences
VAL401 Phase II trial completed
By
Dr Gregoire Pave
01 Nov 2018
Diurnal Group Plc
Life Sciences
Unexpected Phase III trial outcome
By
Dr Gregoire Pave
17 Oct 2018
Advanced Oncotherapy
Life Sciences
Four components integrated
By
Dr Martin Hall
16 Oct 2018
Diurnal Group Plc
Life Sciences
First commercial revenues
By
Dr Martin Hall
04 Oct 2018
Redx Pharma
Life Sciences
Strategy launch
By
Dr Martin Hall
02 Oct 2018
Allergy Therapeutics plc
Life Sciences
2018 full-year results: solid growth
By
Dr Martin Hall
27 Sep 2018
Prev
1
...
6
7
8
9
10
...
17
Next
